Approval of the Audited Financial Statements for the quarter and year ended March 31, 2026 and recommend Final Divided of Rs. 18/- per equity share i.e. 900% of the Face Value of Rs. 2/- ....

Profit growth above 25%EBITDA margin expansionExceptional itemRevenue growth above 20%Results View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹2462.00

prior close

₹2425.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.1%-3.5% vs market

Pharmaceuticals peers, median of 161sector+0.1%-3.7% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+2.0

15m

+1.6

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-0.1-3.5+0.1-3.7

Next day

-8.9-1.2-7.7+0.2-9.1

-8.6-3.7-4.9-1.4-7.2

-9.8-3.1-6.7-1.9-7.9

-8.5-2.0-6.6-1.6-7.0

-7.2-2.4-4.8-1.7-5.6

-6.9-1.9-5.0-2.0-4.9

15d

-8.4-2.4-6.1-0.7-7.8

-8.7-3.9-4.8-1.5-7.2

-0.2-1.2+1.0+3.4-3.6

-6.6+2.9-9.5+5.9-12.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin Limited reported strong FY2026 results with consolidated revenue growing 23% YoY to Rs. 279,580.3 million from Rs. 227,079.0 million. Net profit after tax jumped 62% to Rs. 53,554.7 million from Rs. 33,062.6 million, driven by robust pharmaceutical segment performance and favorable forex gains. The Board recommended a dividend of Rs. 18 per share (900% of face value Rs. 2), aggregating Rs. 8,229.2 million, subject to shareholder approval. Exceptional items included antitrust litigation provisions of Rs. 5,816.9 million, an Astellas settlement of Rs. 8,475.5 million, and a gain of Rs. 6,626.8 million from business divestments. The company also completed acquisitions of VISUfarma B.V. (Rs. 20,902.7 million) and Renascience Pharma Limited during the year.

Likely market impact

Strong earnings growth with PAT up 62% indicates operational efficiency improvement. The clean audit opinion with unmodified reports and EBITDA margin expansion are positive signals for shareholders. However, ongoing litigation provisions and settlement costs remain key monitoring items.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹7,475 Cr	₹5,667 Cr	+31.9%
Operating profit	₹1,919 Cr	₹838.9 Cr	+128.7%
Profit after tax	₹1,469 Cr	₹782.4 Cr	+87.7%
EBITDA margin	31.5%	23.3%	+8.2 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.